Short and Long-term Mortality of Pneumococcal Pneumonia in Adults and Children- A Detailed Scoping Review

Rupalakshmi Vijayan, M.D.*, Shavy Nagpal, M.D.**, Manthi Dissanayake, BA**, Shameera Shaik Masthan, M.D.**, Aiman Fatima, M.D.**, Julio Ramirez, M.D.**

* St Elizabeth Health Centre-Boardman, Ohio **Larkin Community Hospital, Department of Research, South Miami, Florida

Abstract

Streptococcus pneumoniae is a common infectious agent responsible for pneumonia, which can result in serious complications such as meningitis, sepsis, morbidity, and mortality. The objective of this study is to examine the risk factors and complications associated with mortality caused by community-acquired pneumococcal pneumonia in both adults and children. To conduct this research, a thorough literature review was carried out by researchers between May 1, 2021, and August 1, 2021. Various databases, including PubMed, WHO, clinicaltrials.gov, Embase, Web of Science, Cochrane, and Google Scholar, were searched using specific keywords such as mortality, pneumococcal pneumonia, adults, children, and their combinations. The study encompassed patients of all age groups affected by pneumococcal pneumonia, while systematic reviews focusing on other types of pneumonia and non-pneumonia patients were excluded. After eliminating duplicate studies, the search yielded 1783 relevant articles, which underwent title and abstract screening. Ultimately, 8 studies were included in the final review. In conclusion, pneumococcal pneumonia is a significant contributor to mortality among both adults and children. This research emphasizes the importance of implementing effective management strategies to reduce long-term mortality

Introduction

Streptococcus pneumoniae is a bacterial pathogen known to cause pneumonia, which can manifest as invasive pneumococcal disease (IPD) and severe non-invasive lower respiratory disease, both of which can be fatal.[1] Among cases of community-acquired pneumonia (CAP) caused by pneumococcus, approximately 20-30% are classified as invasive pneumococcal pneumonia (invasive pneumonia), while the remaining 70-80% are considered non-invasive pneumonia.[2] Pneumococcal infection is a significant global health concern, contributing to substantial morbidity and mortality.[1] Individuals with chronic conditions such as chronic obstructive pulmonary disease, bronchial asthma, chronic cardiovascular disease, cerebrovascular disease, chronic renal disease, chronic liver disease, or diabetes mellitus, as well as the elderly and immunocompromised, face an increased risk of acquiring pneumococcal pneumonia (PP) and bacteremia.[3] Bacterial pneumococcal pneumonia (BPP) can lead to various complications, ranging from adult respiratory distress syndrome to septic shock and death.[1] Numerous guidelines have been established to promote standardized management of pneumonia, with several studies demonstrating that adherence to these guidelines has resulted in reduced mortality rates.[4]

Over the years, advancements in early detection methods, appropriate antibiotic administration, and consistent clinical management have contributed to a decline in the case fatality rate among patients with pneumococcal pneumonia.[5] This study aims to provide a comprehensive overview of current trends in the prediction and treatment of pneumococcal pneumonia. The research questions guiding this study are (1) to assess short and long-term mortality in adults and children affected by

pneumococcal pneumonia and (2) to evaluate the risk factors and complications associated with mortality caused by pneumococcal pneumonia.

Methods

To gather relevant literature, a search was conducted from January 2016 to May 31st, 2021, utilizing seven databases, namely PubMed, WHO, clinicaltrials.gov, Embase, Web of Science, Cochrane, and Google Scholar. The search terms used included keywords such as Mortality, Pneumococcal Pneumonia, adults, children, and various combinations thereof. The study encompassed patients of all age groups affected by pneumococcal pneumonia, while systematic reviews focusing on other types of pneumonia and non-pneumonia patients were excluded. A comprehensive search strategy, employing an umbrella method, was utilized, and the reference lists of retrieved articles were cross-checked. After the exclusion process, eight articles were selected for the final review. These selected articles were individually reviewed by two authors, and any disagreements were resolved through discussions with a third reviewer, ultimately reaching a consensus among the authors. The review search encompassed studies conducted in different countries worldwide. To eliminate duplicate studies, Endnote X9 software was employed.

Ethical approval

Ethical approval was not required for this study, as public databases were used for obtaining data and patients were not directly involved.

Results

In the 8 studies reviewed, involving 19,137 patients (Study 1-8), significant findings were observed:

A retrospective study in Barcelona from 1997-2016 (Study 1) with 6,403 patients found an overall 30-day mortality rate of 8% for pneumococcal pneumonia. There were no significant changes in mortality over different 5-year periods. A prospective study in Brazil from 2009-2017 (Study 2) involving 186 patients compared adults and elderly individuals with pneumococcal pneumonia. The elderly had a higher 30-day mortality rate but fewer ICU admissions and shorter in-patient stays. An epidemiological study in Europe in 2015 (Study 3) included 21,118 confirmed pneumonia cases, reporting a mortality rate of 14%. Patients with chronic respiratory disorders had a higher risk of bacteremic pneumonia, but their mortality risk was not higher than those without this comorbidity.

Chronic lung illness, such as COPD and bronchial asthma, was identified as an independent risk factor for pneumococcal pneumonia, especially in the elderly (Study 4). Chronic renal illness did not significantly affect mortality in relation to pneumococcal pneumonia (Study 5). Smoking was not found to have a significant effect on the occurrence of pneumococcal pneumonia in the studied age groups (Study 6). A study in the Netherlands from 2004-2012 (Study 7) with 228 invasive pneumonia patients revealed that comorbidities such as chronic cardiac, lung, and hepatic disorders, renal failure, immunosuppression, chronic neurological diseases, HIV, diabetes mellitus, tobacco usage, and alcohol addiction were associated with pneumococcal disease-related mortality.

These findings highlight the impact of various risk factors and comorbidities on mortality rates in pneumococcal pneumonia patients (Study 1-7), [6-25].

Discussion

The most common comorbidities in the studied population were chronic obstructive pulmonary disease (COPD) and bronchial asthma, which were associated with an increased risk of bacteremic pneumonia (adjusted OR: 3.07, 95% CI: 1.23–7.65, p 0.01). Adults with asthma had a 12-17% attributable risk of invasive pneumococcal infections, especially with frequent asthma exacerbations [25,26]. Pneumonia in dialysis patients occurred at a rate of 27.9 per 100 people per year, with a 1-year survival rate of 0.51 [25]. Chronic renal failure was more prevalent in people over 65 years old but did not affect mortality [26]. Splenic volume less than 40 cm3 was found to be significantly associated with mortality within 30 days in patients with pneumococcal pneumonia [30,31,32,33,34]. Alcohol misuse and acid-suppressing drugs were associated with increased mortality [30]. Smoking was not significantly associated with pneumonia in the studied age groups [39,40,41,42]. Childhood pneumococcal vaccination had indirect effects on the incidence of pneumococcal disease [46]. Risk factors for mortality in children with pneumonia included convulsions, age <12 months, lower weight, unsafe water consumption, lower parental education, severity of disease, and presence of co-morbid conditions [47,48,49,50,51].

Greater mortality in children under the age of five was positively associated with the severity of pneumonia [51,52]. Surprisingly, there was no significant link found between pentavalent vaccination status and pneumonia mortality. However, pentavalent vaccination was found to be protective against severe pneumonia. Establishing a link between immunization and mortality was challenging due to the low number of pneumonia deaths and potential misclassification of vaccination status based on parental reports. Modifiable factors such as weight for age and availability of safe drinking water were associated with both severity and death. Additionally, parental education level and the omission of more severe and younger individuals from the study may have contributed to discrepancies. Higher maternal education has been previously associated with improved health outcomes in children, including lower childhood mortality rates [53].

Limitations

Our research has limitations that should be considered. Firstly, we did not have information on cause-specific mortality. Secondly, the severity of in-hospital issues was not extensively documented, and we only knew whether they occurred. Thirdly, our findings may not be applicable to patients with pneumococcal bacteremia without pneumonia or other invasive pneumococcal diseases like meningitis. Fourthly, our study focused on patients with BPP who were treated before the implementation of conjugated vaccinations in addition to the standard pneumococcal polysaccharide vaccine for this patient population [52,53]. Fifthly, we lacked detailed data on antibiotic administration, including timing, route, dose, frequency, and antimicrobial susceptibilities. Finally, there is a possibility of misclassification of serotypes since they were grouped based on previous meta-serotype-specific analysis of case fatality rates [54]. However, if misclassification occurred, it is likely to bias the results towards the null, suggesting that the associations between serotypes and outcomes may be even stronger than previously reported.

Conclusion

Based on our analysis, we have determined that Pneumococcal pneumonia significantly contributes to mortality in both adults and children. We also found that the sensitivity of blood cultures may be

compromised when antibiotics have been previously administered. Therefore, it is crucial to exercise caution and prudence in the use of antibiotics.

References:

1. Kim, G. L., Seon, S. H., & Rhee, D. K. (2017). Pneumonia and Streptococcus pneumoniae vaccine. *Archives of pharmacal research*, *40*(8), 885–893. https://doi.org/10.1007/s12272-017-0933-y
2. Thomas R. E. (2021). Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality. *Geriatrics (Basel, Switzerland)*, *6*(1), 13. https://doi.org/10.3390/geriatrics6010013
3. Restrepo, M. I., Sibila, O., & Anzueto, A. (2018). Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. *Tuberculosis and respiratory diseases*, *81*(3), 187–197. https://doi.org/10.4046/trd.2018.0030
4. Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., ... & Yu, V. L. (2001). Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. *American journal of respiratory and critical care medicine*, *163*(7), 1730-1754.
5. Kaysin, A., & Viera, A. J. (2016). Community-acquired pneumonia in adults: diagnosis and management. *American family physician*, *94*(9), 698-706.
6. .Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001 Jun; 163(7):1730–54. https:// doi.org/10.1164/ajrccm.163.7.at1010 PMID: 11401897
7. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007 Mar 1; 44 Suppl 2: S27–72.
8. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004 Apr; 30 (4):536–55. https://doi.org/10.1007/s00134-004-2210-z PMID: 14997291.
9. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003 Dec 1; 37(11):1405–33.
10. Ruiz LA, España PP, Gómez A, Bilbao A, Jaca C, Aramburu A, et al. Age-related differences in management and outcomes in hospitalized healthy and well-functioning bacteremic pneumococcal pneumonia patients: a cohort study. BMC Geriatr. 2017;17(1):130. http://dx.doi. org/10.1186/s12877-017-0518-0. PMid:28633626.
11. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on communityacquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-9. http://dx.doi.org/10.1136/thoraxjnl-2015-206780. PMid:26219979.
12. Adamuz J, Viasus D, Jiménez-Martínez E, Isla P, Garcia-Vidal C, Dorca J, et al. Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. J Infect. 2014;68(6):534-41. http://dx.doi.org/10.1016/j.jinf.2014.02.006. PMid:24534605

13. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-65. http://dx.doi.org/10.1086/518849. PMid:17578773.
14. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017;12:3457-68. http://dx.doi.org/10.2147/COPD.S140378 PMid:29255353.
» http://dx.doi.org/10.2147/COPD.S140378
15. .Dodd KE, Mazurek JM. Pneumococcal vaccination among adults with work-related asthma. Am J Prev Med. 2017;53(6):799-809. http://dx.doi.org/10.1016/j.amepre.2017.07.022 PMid:28964578.
» http://dx.doi.org/10.1016/j.amepre.2017.07.022
16. Vandecasteele SJ, Ombelet S, Blumental S, Peetermans WE. The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease. Clin Kidney J. 2015;8(3):318-24. http://dx.doi.org/10.1093/ckj/sfv030 PMid:26034594.
» http://dx.doi.org/10.1093/ckj/sfv030
17. Huang ST, Lin CL, Chang YJ, Sher YP, Wu MJ, Shu KH, et al. Pneumococcal pneumonia infection is associated with end-stage renal disease in adult hospitalized patients. Kidney Int. 2014;86(5):1023-30. http://dx.doi.org/10.1038/ki.2014.79 PMid:24694991.
» http://dx.doi.org/10.1038/ki.2014.79
18. Chun CS, Weinmann S, Riedlinger K, Mullooly JP. Passive cigarette smoke exposure and other risk factors for invasive pneumococcal disease in children: a case-control study. Perm J. 2015;19(1):38-43. http://dx.doi.org/10.7812/TPP/14-010 PMid:25431997.
» http://dx.doi.org/10.7812/TPP/14-010
19. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000;342(10):681-9. http://dx.doi.org/10.1056/NEJM200003093421002 PMid:10706897.
» http://dx.doi.org/10.1056/NEJM200003093421002
20. .Morton JB, Morrill HJ, La Plante KL, Caffrey AR. Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with *Streptococcus pneumoniae* infections. Vaccine. 2017;35(13):1692-7. http://dx.doi.org/10.1016/j.vaccine.2017.02.026 PMid:28245940.
» http://dx.doi.org/10.1016/j.vaccine.2017.02.026

21. Kalin M. Pneumococcal serotypes and their clinical relevance. Thorax 1998;53 (3):159–62
22. Koivula I, Sten M, Makela PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999;159(14):1550–5.
23. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009;6(5):e1000081.
24. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7(10). http://dx.doi.org/10.1371/journal. pmed.100034
25. Lujan M, Gallego M, Belmonte Y, Fontanals D, Valles J, Lisboa T, et al. Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 2010;36(5):1073–9.
26. Wagenvoort GH, Knol MJ, de Melker HE, Vlaminckx BJ, van der Ende A, Rozenbaum MH, et al. Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands. Vaccine 2016;34(3):334–40.

27. Wagenvoort GH, Sanders EA, Vlaminckx BJ, Elberse KE, de Melker HE, van der Ende A, et al. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2–6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands. Vaccine 2016;34(8):1077–85. http://dx.doi.org/10.1016/j.vaccine.2015.12.066. Epub 2016 Jan 8. PMID: 26778420.
28. van Mens SP, van Deursen AM, de Greeff SC, de Melker HE, Schouls LM, van der Ende A, et al. Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared. Eur J Clin Microbiol Infect Dis 2015;34(1):115–22
29. Eurich DT, Sadowski CA, Simpson SH, et al. Recurrent communityacquired pneumonia in patients starting acid-suppressing drugs. Am J Med 2010;123:47–53.
30. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011;378:86e97. https://doi.org/10.1016/S0140-6736(10)61493-6.
31. Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity 2013;39:806e18. https://doi.org/10.1016/j.immuni.2013.10.010.
32. Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. Sci Immunol 2019;4:eaau6085. https://doi.org/10.1126/ sciimmunol.aau6085.
33. William BM, Corazza GR. Hyposplenism: a comprehensive review. Part I: basic concepts and causes. Hematology 2007;12:1e13. https://doi.org/10.1080/ 10245330600938422.
34. O'Neal Jr HR, Niven AS, Karam GH. Critical illness in patients with asplenia. Chest 2016;150:1394e402. https://doi.org/10.1016/j.chest.2016.03.044.
35. William BM, Thawani N, Sae-Tia S, Corazza GR. Hyposplenism: a comprehensive review. Part II: clinical manifestations, diagnosis, and management. Hematology 2007;12:89e98. https://doi.org/10.1080/10245330600938463.
36. Higashi T, Kimura S, Matsumoto S, Muto N, Yamanoi T, Nakamura K, et al. Relationship between the appearance of Howell-Jolly bodies and spleen volume calculated by CT. J Jpn Soc Intens Care Med 2013;20:395e9. https:// doi.org/10.3918/jsicm.20.395
37. Corazza GR, Tarozzi C, Vaira D, Frisoni M, Gasbarrini G. Return of splenic function after splenectomy: how much tissue is needed? Br Med J 1984;289: 861e4. https://doi.org/10.1136/bmj.289.6449.861
38. van Werkhoven CH, Huijts SM. Vaccines to prevent pneumococcal community-acquired pneumonia. Clin Chest Med 2018;39:733e52. https:// doi.org/10.1016/j.ccm.2018.07.007
39. Bello S, Menendez R, Torres A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest. 2014;146(4):1029-1037.
40. Grau I, Ardanuy C, Calatayud L, Schulze MH, Linares J, Pallares R. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis. 2014;25:59-64
41. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3):144-154
42. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000;342(10):681-689
43. Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377-384.
44. Song JY, Eun BW, Nahm MH. Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. Infect Chemother. 2013; 45: 351–66. https://doi.org/10.3947/ic.2013.45.4.351 PMID: 24475349

45. Song JY, Nahm MH, Cheong HJ, Kim WJ. Impact of preceding flu-like illness on the serotype distribution of pneumococcal pneumonia. PLoS One. 2014; 9: e93477. https://doi.org/10.1371/journal.pone. 0093477 PMID: 24691515
46. Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One. 2017; 12: e0177342. https://doi.org/10.1371/ journal.pone.0177342 PMID: 28498857
47. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174(5):986-993.
48. Bari M, Siddiqui A, Alam T, Hossain A. Risk factors of pneumonia in children– A community survey, vol. 20. 2009.
49. Ghimire M, Bhattacharya SK, Narain JP. Pneumonia in South-East Asia region: public health perspective. Indian J Med Res. 2012;135(4):459–68.
50. Sonego M, Pellegrin MC, Becker G, Lazzerini M. Risk factors for mortality from acute lower respiratory infections (ALRI) in children under five years of Age in Low and middle-income countries: a systematic review and metaanalysis of observational studies. PLoS One. 2015;10(1):e0116380.
51. Chisti MJ, Tebruegge M, La Vincente S, Graham SM, Duke T. Pneumonia in severely malnourished children in developing countries - mortality risk, aetiology and validity of WHO clinical signs: a systematic review. Trop Med Int Health. 2009;14(10):1173–89.
52. Ferreira S, Sant'anna CC, March Mde F, Santos MA, Cunha AJ. Lethality by pneumonia and factors associated to death. J Pediatr (Rio J). 2014;90(1):92–7.
53. Gakidou E, Cowling K, Lozano R, Murray CJ. Increased educational attainment and its effect on child mortality in 175 countries between 1970 and 2009: a systematic analysis. Lancet. 2010;376(9745):959–74.

Figure 1: Prisma Flow Chart for study acquisition



Flowchart for studies included